RHHBY

Roche’s Breast Cancer Drug Approval Is Just the Beginning

It might have been dismissed as irrelevant by most investors, but Roche and its Perjeta could reshape the breast cancer drug landscape. More 

2 Major Pharmaceutical Rivals to Share Drug Data

AstraZeneca and Roche will share drug research data with a third company to build a compound library to accelerate drug development and lower costs. More 

Study: New Bird Flu Resistant to Roche’s Tamiflu

Physicians in China have noted that some patients with bird flu are not responding to treatment with Tamiflu, the only known drug used to fight the infection. More 

India Drops Patent Bomb on Novartis

India's ruling on a Novartis patent draws a clear line of favor between generic drug companies and Big Pharma. More 

AstraZeneca Plans 2,300 More Job Cuts

AstraZeneca will trim its payroll by another 2,300 jobs, just days after cutting 1,600 other workers, as part of its latest restructuring. More 

FDA Warns Docs as More Fake Cancer Drugs Hit U.S.

The FDA is warning doctors that it has found another counterfeit batch of the cancer-fighting drug Avastin that contains no active ingredients. More 

Biotech Movers: Keryx Jumps, Sarepta Slips

Among last week's highlights, Keryx jumps on a solid Phase III trial, Sarepta gets pounded from a fake tweet and Halozyme suffers from analyst downgrades. More